The standard treatment of Crohn’s disease (Crohn’s disease) is based on the “step-up” strategy. However, results from the PROFILE study indicate that in newly diagnosed Crohn’s disease, early use of a TNF-α inhibitor in combination with an immunomodulator is significantly more effective than stepwise escalation. The recently published results of several years of follow-up show that this also applies to the longer-term outcomes. As interesting as these study results are, in terms of a “best practice” approach, the guideline advises that the respective course of treatment should be assessed individually using surrogate parameters and adjusted accordingly depending on the response.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- From symptom to diagnosis
Multilocular cystic renal cell carcinoma (MCRCC)
- Shaping the Future with LLM & Co.
AI in Everyday Clinical Practice: Friend or Foe?
- Ulcerative colitis: current evidence on anti-inflammatory therapies
Remission induction and maintenance with biologics and JAK-i
- Bronchiectasis
New strategies against neutrophilic inflammation
- IBD in childhood
Pneumococcal vaccination without negative consequences
- Plastic surgery and reconstructive microsurgery for DFS
Functional limb preservation between infection control, vascular medicine and resurfacing
- Seborrheic Dermatitis in Adults and Adolescents
Current State of Knowledge and New Therapeutic Approaches
- Orthobiologics for knee osteoarthritis